Separate the treatments you offer
Prepare distinct service descriptions with qualified review of uses and limitations. Visitors can understand the options without a cure or response-rate promise.
For TMS and ketamine clinics
Patients need clear consultation, eligibility and cost information. LunahUP helps prepare distinct TMS, esketamine or ketamine pages only where offered, using approved facts and qualified review of treatment claims before publication.
AI helps prepare. Your people approve.
What gets in the way
People may arrive with expectations about eligibility, benefits or a particular treatment that a website cannot establish for them.
The LunahUP approach
Describe the actual services and consultation process using wording your responsible team reviews.
Bring a treatment page and the evidence supporting its current claims. We review the gap, prepare proposed work from your confirmed facts, and let your team approve the change.
This is the improvement we work toward. Results depend on the work, your market and what can be measured.
A treatment headline cannot establish suitability or coverage. Explain the assessment process and questions the practice needs to confirm.
Prepare distinct service descriptions with qualified review of uses and limitations. Visitors can understand the options without a cure or response-rate promise.
Use approved eligibility and first-visit information. A prospective patient can see how to ask about assessment while clinical decisions stay with clinicians.
Prepare approved self-pay, insurance and authorization information. Distinguish a published service description from an individual coverage decision.
When someone asks an assistant whether "TMS therapy is covered by insurance in [city]", configured samples record the reply, the date and the pages it relied on.
TMS and ketamine marketing without overpromising
TMS is delivered by devices the FDA has cleared for specific uses, beginning with major depressive disorder. Esketamine nasal spray is an FDA-approved prescription drug for treatment-resistant depression, given only in certified settings under a safety program that includes monitoring after each dose. Ketamine by infusion is approved as an anesthetic, so its use for depression is off-label.
Patients rarely know these differences, and many pages blur them. A page for each treatment you offer, each describing its own status accurately, is both the honest approach and the one that matches how people search.
Most people arrive after other treatments have not worked well enough. They want to know whether they might qualify, what the consultation involves, and how long a course of treatment takes before they commit to the first visit.
Describe your assessment process and the kinds of history your clinicians review, without implying that a consultation guarantees treatment. Leave the clinical decision where it belongs.
Coverage for TMS and esketamine often depends on prior authorization and on documented earlier treatments; infusion ketamine is frequently self-pay. Families need this explained in plain words before they call.
List the plans you have verified, explain what authorization usually requires, and give self-pay figures your billing team confirms. Re-check the list before anything is reused, because payer policies change.
TMS usually means sessions on most weekdays for several weeks; esketamine involves supervised visits with a monitoring period afterward. Practical detail about scheduling, time off work and getting home helps people plan.
Describe your own schedule and setting, not general averages, and say what someone should do if they miss a session.
“Cure”, “breakthrough”, “miracle” and unsupported response percentages invite regulatory problems and erode trust. If you publish outcome figures, cite where they came from and how they were measured, with your clinicians’ approval.
Never present off-label use as approved, and keep at-home ketamine products out of your marketing unless your clinical team has reviewed exactly what you offer and how.
LunahUP’s own Search Console shows practices searching phrases like “marketing agency for ketamine clinics” and “content marketing for TMS clinics”. They are looking for someone who understands these limits, not just someone who can buy ads.
That is the bar we set: content a clinician would sign, structured so search engines and AI assistants can understand each treatment correctly.
Many TMS and esketamine patients arrive through a psychiatrist, primary care clinician or therapist who has run out of options. Referrers want different facts from patients: who is a candidate, which records to send, how soon you can consult, whether the patient returns to them afterward and how you report back.
A short referral page with a clear way to send records answers those questions without a phone call. Keep it free of outcome promises, as you would a patient page, and confirm the steps with your intake team before it goes live. Never offer anything of value in exchange for referrals, and check any referral arrangement with counsel.
People search by treatment, by condition and by place: “TMS near me”, “esketamine clinic in [city]”, “ketamine infusion for depression [city]”, “does insurance cover TMS”. Others search for help after medication has not worked, without naming any treatment. Your Search Console data shows which of these already bring your site into results.
Give each important search one home. Treatment-and-city searches belong on the treatment page for that location, and coverage questions on an insurance page. Broader searches such as “depression not getting better” are best met with a plain explainer that describes options and leads to a consultation, without suggesting any one treatment is right.
Google restricts prescription drug terms in ads, keywords and landing pages in the US, and it does not allow promotion of speculative or experimental medical treatments. An ad that names a medication, or a landing page built around one, may be limited or disapproved. Check the current policy for each treatment before planning spend.
Targeting people by health condition is also off the table, so campaigns depend on what people type. One workable approach, for example, is a search ad for depression treatment consultations in your city that leads to a page explaining each treatment’s status and the consultation step. Your medical director approves the wording first.
Common ones: copying a device maker’s marketing text onto your page as if it were your own; listing conditions your device is not cleared for; showing a ketamine price that leaves out the consultation or monitoring visits; and leaving out what a patient must arrange after a session, such as a ride home, when your protocol requires it.
Another is publishing patient stories or symptom score changes from a few patients as if they showed what everyone can expect, or without the patient’s written authorization. Each of these can weaken trust with patients, referrers and payers. A plain, accurate page is the stronger asset over time.
Track consultation requests by treatment, not just total calls, and note how many people turned out not to be candidates or could not get coverage. A page that brings many calls from people who are not eligible may need clearer candidacy or insurance wording rather than more traffic.
In Search Console, follow the treatment-and-city searches and the insurance questions for each page. Ask new patients how they heard about you, including whether a clinician referred them. Over several months, that shows which pages and referral relationships bring the consultations that fit your clinic.
LunahUP’s founder runs an outpatient telepsychiatry practice, not a TMS or ketamine clinic. We bring search research, structure and drafts built from your confirmed facts; your medical director approves every claim before it is published.
If a payer or regulator ever asks what your site claimed last spring, the dated record of every approved edit answers it.
Marketing a TMS or ketamine clinic means explaining what each treatment is, what it is cleared or approved for, who is a candidate, what a course of treatment involves, and how insurance and prior authorization work. The distinctions matter: TMS devices are FDA-cleared for specific indications, esketamine (Spravato) is FDA-approved for specific depression indications under a restricted program, and IV ketamine for depression is used off-label. Pages and ads should describe each accordingly.
No "cure", "miracle" or response-rate claims you cannot document.
Off-label use is not presented as approved.
People who once searched for depression treatment are not chased with ads afterward.
Try the work for yourself
Review up to four public pages, their findings and suggested next steps. Email unlocks the report; follow-up is optional.
Check my website →Turn one CSV export into a shortlist you can inspect and download. Your file stays in your browser, with no email gate.
Find my opportunities →No export yet? Try the Opportunity Finder’s clearly labeled fictional sample. It demonstrates the tool, not a customer result.
Get help with the next step
Bring a treatment page and the evidence supporting its current claims. Search plans start at $299/month, month to month, with no setup fee. Website projects and upkeep have separate options. Every client’s LunahUP Provider Directory profile is set up as part of the service.
See full plans and pricing →We follow up to arrange a time. No obligation.
Only rates you can document, with where they came from. Require a documented source, measurement method and authorized approval before publishing numerical results.
Accurately: as a treatment some clinicians use off-label, with your consultation process. It is not presented as FDA-approved for depression.
No. They are different treatments with different candidacy, schedules and coverage, and people search for each by name.
Yes, stating what you have verified about each insurer's coverage and authorization, re-checked before it is reused.
It keeps every claim inside what each treatment is actually approved or cleared for, explains candidacy and cost before the consultation, and leaves outcome numbers out unless your medical director can document them. LunahUP drafts that content and your clinicians sign off on it.
A page for each treatment you offer, a clear course-of-treatment schedule, an insurance and prior authorization explainer, and answers to “am I a candidate?”. Social posts can reuse that approved material; managing social accounts is only included when it is agreed in scope.
Treat TMS, esketamine and infusion ketamine as separate services with separate pages, describe each one’s regulatory status accurately, and make the consultation the next step. Search, AI answers and any agreed ads all follow from those pages.
Expect months, not weeks, for search. New pages have to be crawled and earn trust before they rank, and referral relationships take time to build. Paid search can start sooner once eligibility and wording are approved, but results still depend on what people in your area search for.
Only if your clinical team offers it and has reviewed exactly how it is prescribed, supplied and monitored. Ketamine used for depression outside esketamine’s approved program is off-label, and at-home use raises extra safety questions. LunahUP will not draft wording that presents it as approved for depression.
If you offer both, yes, as long as your device is cleared for each use you describe. People search for each by name, and candidacy, schedules and coverage differ. Confirm the cleared indications for your specific device in the FDA database before either page is written.
What a consultation costs, what a full course costs for self-pay patients, what insurers typically require before authorizing, and what is not included. Use figures your billing team confirms and show when they were last checked. Avoid “starting at” prices that leave out parts of the course people will need.
Explore the tools on your own, or bring your priorities to a conversation with LunahUP.
No rankings, citations or results are guaranteed. Updated 2026-10-26.